Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle ...

– Treatment with Mitapivat Demonstrated Statistically Significant Improvement in Hemoglobin Response Compared to Placebo –

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,United States ,San Diego ,California ,Texas ,Houston ,American ,Modupe Idowu ,Dan Budwick ,Sarah Gheuens ,Chris Taylor ,Mcgovern Medical School ,Gut Health ,Agios Pharmaceuticals Inc ,Exchange Commission ,American Society Of Hematology ,Corporate Communications ,Agios Pharmaceuticals ,European Union ,Nasdaq ,Ut Physicians Comprehensive Sickle Cell Center ,Hemoglobin Response Compared ,Improvements Observed ,Annualized Rates ,Sickle Cell Pain Crises ,Participants Treated ,Ghost Live ,Webcast Investor Event ,American Society ,Annual Meeting ,Texas Health Science Center ,Comprehensive Sickle Cell Center ,Multicenter Study ,Patients With Sickle Cell Disease ,Abstract Session ,Cell Disease ,Sickle Cell Trait ,Excluding Thalassemias ,Disease Modifying Therapeutics ,Sickle Cell ,Substrates Including Hormonal Contraceptives ,Prescribing Information ,Product Characteristics ,Private Securities Litigation Reform Act ,Region ,